Condition
Glioma (including glioblastoma)
A glioma is a tumor that starts in the support cells of the brain. Gliomas range from slow-growing tumors to fast-growing glioblastoma, and treatment depends on the exact type.
General information, not medical advice. In an emergency call 911. Full disclaimer
What it is
The brain has nerve cells and support cells called glial cells. A glioma is a tumor that starts in glial cells. Gliomas include astrocytomas, oligodendrogliomas, and glioblastoma. [3]
Doctors give each tumor a grade. A low grade means the cells look closer to normal and grow slowly. A high grade means the cells grow fast. Glioblastoma is the fastest-growing type. [3]
Current names. Since 2021, the World Health Organization (WHO) uses gene tests as well as the microscope to name these tumors. The main adult types are now:
- Astrocytoma, IDH-mutant (grade 2, 3, or 4)
- Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (grade 2 or 3)
- Glioblastoma, IDH-wildtype (grade 4)
IDH is a gene. "Mutant" means the tumor has a change in it. "Wildtype" means it does not. Grades are now written as plain numbers, such as grade 2. [4] Older reports and some survival numbers still use the earlier names, such as "anaplastic astrocytoma."
Symptoms
Symptoms depend on where the tumor is and how big it is. They can include:
- Headache, often in the morning or eased by vomiting
- Seizures
- Problems with vision, hearing, or speech
- Nausea and vomiting
- Changes in mood, personality, or focus
- Weakness, loss of balance, or trouble walking
- Unusual sleepiness
How it is diagnosed
The main test is an MRI scan with contrast dye. A scan can suggest a glioma, but it cannot name the exact type. For that, the team needs a tissue sample. This may come from a needle biopsy or from surgery to remove the tumor. [3]
The lab then tests the tissue for gene changes such as IDH. These results set the type and grade. They also guide treatment and help predict the outlook. [4] [5]
How it changes over time
Gliomas usually grow into nearby brain. That makes them hard to remove completely. Grade 2 tumors grow slowly, but they can come back after treatment and some turn into a higher grade. Grade 4 tumors grow fast and usually cannot be fully removed. [3]
Outlook. These numbers describe groups, not one person. They come from US registry data for people treated from 2004 to 2020, so newer treatments are not fully reflected. "Relative survival" compares people with the tumor with people in the general population. [6]
| Older tumor name | 5-year relative survival, age 15 to 39 | 5-year relative survival, age 40 and older |
|---|---|---|
| Oligodendroglioma | about 93 out of 100 | about 79 out of 100 |
| Low-grade diffuse astrocytoma | about 79 out of 100 | about 34 out of 100 |
| Anaplastic astrocytoma | about 64 out of 100 | about 21 out of 100 |
| Glioblastoma | about 28 out of 100 | about 6 out of 100 |
Tumor location, how much can be removed, and gene changes also affect the outlook. [6]
Treatment choices
A team of surgeons, radiation doctors, and cancer doctors usually plans care together. Treatment depends on the type, grade, location, and your health. [3] [5]
Surgery. Surgery gives tissue for diagnosis. When safe, the surgeon removes as much tumor as possible. See craniotomy for brain tumor removal. In glioblastoma, studies link more complete removal with longer survival, but the quality of this evidence is moderate to low. [7]
Glioblastoma. The usual plan is surgery, then radiation with a chemotherapy pill called temozolomide, then more temozolomide. [3] In a trial of 573 adults:
- Half lived at least 14.6 months with radiation plus temozolomide, and 12.1 months with radiation alone. [8]
- At 2 years, about 27 out of 100 were alive with the combined treatment, compared with about 11 out of 100 with radiation alone. [9]
- At 5 years, about 10 out of 100 were alive with the combined treatment, compared with about 2 out of 100. [9]
Lower-grade gliomas. Options include surgery with or without radiation and chemotherapy. [3] For grade 2 IDH-mutant gliomas, a newer pill called vorasidenib blocks the changed IDH protein. In a trial of 331 people who had only had surgery, it delayed tumor growth. Half had growth within 27.7 months on vorasidenib, compared with 11.1 months on a placebo (dummy pill). Serious side effects were more common with the drug, about 23 out of 100 compared with about 14 out of 100. [10]
Supportive care. This treats symptoms such as seizures and brain swelling. [3] Any change in your medicine should come from your treating team.
Clinical trials are an option at any stage. [3]
Questions to ask
- What is the full name and grade of my tumor, including the IDH result?
- How much of the tumor can be removed safely, and what could I lose?
- What do radiation, chemotherapy, or a targeted pill add in my case?
- Is there a clinical trial that fits me?
- Who should I call if I have a seizure or new symptoms?
Sources
- Signs and Symptoms of Stroke. Centers for Disease Control and Prevention. Published May 19, 2026. Open source
- First Aid for Seizures. Centers for Disease Control and Prevention. Published May 15, 2024. Open source
- PDQ Adult Treatment Editorial Board. Adult Central Nervous System Tumors Treatment (PDQ): Patient Version. National Cancer Institute. Published October 28, 2026. Open source
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. Published August 2, 2021. Open source
- Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-186. Published December 8, 2020. Open source
- Survival rates for selected adult brain and spinal cord tumors. American Cancer Society. Published January 5, 2026. Open source
- Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460-1469. Published November 1, 2016. Open source
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. Published March 10, 2005. Open source
- Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466. Published March 9, 2009. Open source
- Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589-601. Published June 4, 2023. Open source